| 1. |
- Fico, Giuseppe, et al.
(författare)
-
What do healthcare professionals need to turn risk models for type 2 diabetes into usable computerized clinical decision support systems? Lessons learned from the MOSAIC project
- 2019
-
Ingår i: BMC Medical Informatics and Decision Making. - : Springer Science and Business Media LLC. - 1472-6947. ; 19
-
Tidskriftsartikel (refereegranskat)abstract
- Background: To understand user needs, system requirements and organizational conditions towards successful design and adoption of Clinical Decision Support Systems for Type 2 Diabetes (T2D) care built on top of computerized risk models. Methods: The holistic and evidence-based CEHRES Roadmap, used to create eHealth solutions through participatory development approach, persuasive design techniques and business modelling, was adopted in the MOSAIC project to define the sequence of multidisciplinary methods organized in three phases, user needs, implementation and evaluation. The research was qualitative, the total number of participants was ninety, about five-seventeen involved in each round of experiment. Results: Prediction models for the onset of T2D are built on clinical studies, while for T2D care are derived from healthcare registries. Accordingly, two set of DSSs were defined: the first, T2D Screening, introduces a novel routine; in the second case, T2D Care, DSSs can support managers at population level, and daily practitioners at individual level. In the user needs phase, T2D Screening and solution T2D Care at population level share similar priorities, as both deal with risk-stratification. End-users of T2D Screening and solution T2D Care at individual level prioritize easiness of use and satisfaction, while managers prefer the tools to be available every time and everywhere. In the implementation phase, three Use Cases were defined for T2D Screening, adapting the tool to different settings and granularity of information. Two Use Cases were defined around solutions T2D Care at population and T2D Care at individual, to be used in primary or secondary care. Suitable filtering options were equipped with "attractive" visual analytics to focus the attention of end-users on specific parameters and events. In the evaluation phase, good levels of user experience versus bad level of usability suggest that end-users of T2D Screening perceived the potential, but they are worried about complexity. Usability and user experience were above acceptable thresholds for T2D Care at population and T2D Care at individual. Conclusions: By using a holistic approach, we have been able to understand user needs, behaviours and interactions and give new insights in the definition of effective Decision Support Systems to deal with the complexity of T2D care.
|
|
| 2. |
- Bladen, Catherine L., et al.
(författare)
-
The TREAT-NMD Duchenne Muscular Dystrophy Registries : Conception, Design, and Utilization by Industry and Academia
- 2013
-
Ingår i: Human Mutation. - : Hindawi Limited. - 1059-7794 .- 1098-1004. ; 34:11, s. 1449-1457
-
Tidskriftsartikel (refereegranskat)abstract
- Duchenne muscular dystrophy (DMD) is an X-linked genetic disease, caused by the absence of the dystrophin protein. Although many novel therapies are under development for DMD, there is currently no cure and affected individuals are often confined to a wheelchair by their teens and die in their twenties/thirties. DMD is a rare disease (prevalence<5/10,000). Even the largest countries do not have enough affected patients to rigorously assess novel therapies, unravel genetic complexities, and determine patient outcomes. TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients. The harmonized implementation of national and ultimately global patient registries has been central to the success of TREAT-NMD. For the DMD registries within TREAT-NMD, individual countries have chosen to collect patient information in the form of standardized patient registries to increase the overall patient population on which clinical outcomes and new technologies can be assessed. The registries comprise more than 13,500 patients from 31 different countries. Here, we describe how the TREAT-NMD national patient registries for DMD were established. We look at their continued growth and assess how successful they have been at fostering collaboration between academia, patient organizations, and industry.
|
|
| 3. |
- Guillén, Sergio, et al.
(författare)
-
IoT European Large-Scale Pilots – Integration, Experimentation and Testing
- 2017
-
Ingår i: Cognitive Hyperconnected Digital Transformation. - New York : Taylor & Francis. ; , s. 221-282
-
Bokkapitel (refereegranskat)abstract
- The IoT European Large-Scale Pilots Programme includes the innovation consortia that are collaborating to foster the deployment of IoT solutions in Europe through the integration of advanced IoT technologies across the value chain, demonstration of multiple IoT applications at scale and in a usage context, and as close as possible to operational conditions.The programme projects are targeted, goal-driven initiatives that propose IoT approaches to specific real-life industrial/societal challenges. They are autonomous entities that involve stakeholders from the supply side to the demand side, and contain all the technological and innovation elements, the tasks related to the use, application and deployment as well as the development, testing and integration activities.This chapter describes the IoT Large Scale Pilot Programme initiative together with all involved actors. These actors include the coordination and support actions CREATE-IoT and U4IoT, being them drivers of the programme, and all five IoT Large-Scale Pilot projects, namely ACTIVAGE, IoF2020, MONICA, SynchroniCity and AUTOPILOT.ot projects, namely ACTIVAGE,IoF2020, MONICA, SynchroniCity and AUTOPILOT.
|
|
| 4. |
- Bravo, L, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 5. |
- Tabiri, S, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
